How Misaligned Pharma and Diagnostic Timelines Are Slowing Targeted Therapy Access
From Capability to Readiness
How New Oligonucleotide Modalities Are Reshaping Preclinical Development
The Missing Middle of Pharma Personalisation
Managing Biopharma R&D Pipelines in an Era of Scientific Innovation
EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Pharmaceutical Quality Management in the American Drug Manufacturing Industry: FDA Standards, Quality Systems and Process Control
Imagine a plant that makes a blood pressure tablet Every batch passes its final test but nobody noticed that the blending step has been drifting for months One day a batch fails dissolution Then another Then the FDA shows up
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
Identification of flavonoids from natural products against hyperlipidaemia through computational approaches
Over the centuries hyperlipidaemia has been recognised as a major risk factor contributing to cardiovascular disease CVD Current research increasingly explores natural compounds such as flavonoids for their potential lipidlowering effects This study evaluated pharmacological potential
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Why Great Science Still Fails at the Regulatory Finish Line
Lakshmi
Pharmaceutical organizations are built to prove a molecule works. Regulators, at the decision point, ask something else: can it be reliably made, have the sites been verified, does the trial design su...
-
2
The Future of Drug Pricing Reforms: What Americans Need to Know
Kate Williamson
High costs of drugs have ignited legislative measures meant to bring down cost of these commodities. This is particularly the case in the U. S. Some of the key measures which have been included are Me...
-
3
How AI Is Changing Drug Discovery and Pharmaceutical R&D in the U.S.
Lakshmi
Artificial intelligence has become permanent infrastructure in U.S. pharmaceutical R&D, yet the first clinical evidence reveals a sharp asymmetry: AI-discovered molecules clear Phase 1 far more of...
-
4
Decentralization - The Future of Clinical Trials
Nikhila Shashikanth
Decentralized clinical trials (DCTs) leads with a premise to leverage technology to transform the traditional clinical trials model. Incorporating digital tools, telemedicine, and real-world data, DCT...
-
5
One Health and Antimicrobial Resistance
Ramendra Pati Pandey
Gajala Deethamvali Ghouse Peer
Carlos R Prudencio
Antonio Charlys da Costa
Elcio Leal
Chung-Ming Chang
It is for the most part recognized that we share many elements with other creature species, which are surely pertinent when the ideas of health and disease are talked about. The term 'One Health&#...
press releasesRead more...
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent BioSolutions Inc announced that it has received a modification exercising an option period under its existing delivery order valued at up to million to supply BioThrax Anthrax Vaccine Adsorbed to the US Department of War DoW The first delivery which is valued at approximately
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Evommune Inc a clinicalstage biotechnology company developing therapies for chronic inflammatory diseases and Hinova Pharmaceuticals Inc SSE today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater China
Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding €0.5 Billion
AGC Biologics has expanded its existing longterm manufacturing agreement with a global pharmaceutical company adding a second supply node at the CDMOs Copenhagen facility The expansion which builds on the existing agreement anchored at AGC Biologics
Newleos Announces $15.5 Million NIH Grant and Receipt of FDA Fast Track Designation for NTX-2001 to Treat Substance Use Disorders
Newleos Therapeutics Inc a clinicalstage biotechnology company developing innovative treatments for neuropsychiatric disorders today announced that the National Institute on Drug Abuse NIDA part of the National Institutes of Health NIH has awarded the company up to million to fund the development o...
Events Read more...
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
10 - 12
Nov 2026Lab Asset & Facility Management Summit
The Westin Boston Seaport Dist...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
LATEST NEWSRead more...
Polaris Rx Selected by Bristol Myers Squibb to Dispense ZENBEXUS™ (iberdomide), the First FDA-Approved CELMoD Therapy for Multiple Myeloma
Polaris Rx announced today that it has been selected by Bristol Myers Squibb to dispense ZENBEXUS iberdomide the first cereblon E ligase modulator CELMoD therapy approved by the US Food and Drug Administration FDA ZENBEXUS is approved in combination with daratumumab
Moleculent Introduces Glimt, the First Automated Instrument for Functional Profiling of Cell-Cell Interactions in Human Tissue
Moleculent AB the life sciences technology company pioneering functional profiling today announced Glimt an automated platform that detects cellcell interactions directly in formalinfixed paraffinembedded FFPE tissue The Glimt platform is now available to selected academic
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Rhythm Pharmaceuticals Inc announced an amendment to the global exclusive license agreement with LG Chem Ltd for bivamelagon an investigational oral smallmolecule melanocortin receptor MCR agonist The Company also announced a fiveyear term loan facility led by KKR
SCIEX Launches LeadScape Compatible with SCIEX OS Software to Accelerate High-Throughput Drug Candidate Evaluation
SCIEX a Danaher company and leader in life science analytical technologies today announced the launch of LeadScape compatible with SCIEX OS software a new highthroughput workflow solution that accelerates drug candidate evaluation Developed by Sound Analytics the software
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
Denali Therapeutics Inc announced that AVLAYAH tividenofusp alfaeknm has been recognized as the Best Biotechnology Product of by The Galien Foundation AVLAYAH is the first biologic approved by the US Food and Drug Administration FDA that is specifically designed to cross the bloodbrain barrier and...
Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors
Doximity Inc the leading digital platform for US medical professionals has launched DoseCheck a free additional safety layer in Doximity Ask that instantly checks every AIgenerated medication dosing claim against a structured drug database to reduce treatment
